findmyKOL
Clinical trialNCT02395016CompletedPhase 3Interventional

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

SponsorBiotech Pharmaceutical Co., Ltd.Enrollment90Pancreatic Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Affiliated Hospital of Military Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Chinese Academy of Medical Sciences Cancer Hospital

    Beijing, Beijing Municipality, China

  • Pla General Hospital (301 Hospital)

    Beijing, Beijing Municipality, China

  • Fujian Provincial Tumor Hospital

    Fuzhou, Fujian, China

  • Fuzhou General Hospital of Nanjing Military Region

    Fuzhou, Fujian, China

  • Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Jiangyin City People'S Hospital

    Jiangyin, Jiangsu, China

  • Jiangsu Province Tumor Hospital

    Nanjing, Jiangsu, China

  • Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • First People'S Hospital Cancer Center, Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, China

  • Shanghai Changhai Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Jiaotong University Affiliated Ruijin Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Affiliated Xijing Hospital, Fourth Military Medical University

    Xi’an, Shanxi, China

  • General Hospital of Chengdu Military Region

    Chengdu, Sichuan, China

  • First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2015
Primary completion
30 Nov 2021
Completion
30 Nov 2021
Last update posted
4 Apr 2024
Registered enrollment
90
Registry id
NCT02395016

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.